REGOBONE-CHONDRO

NCT02389244 📎

Regimen

Experimental
Regorafenib 160 mg PO QD (3 weeks on / 1 week off)
Control
Placebo with optional crossover at progression

Population

Metastatic or locally advanced progressive chondrosarcoma (conventional and dedifferentiated subtypes allowed), progressed on or intolerant to at least one prior systemic line

Key finding

Regorafenib doubled short-term non-progression rate vs placebo and delayed PFS in advanced chondrosarcoma — again without objective responses, consistent with a disease-stabilization paradigm. Randomized placebo-controlled evidence is rare in this tumor.

Source: PMID 33895682

Timeline

    Guideline citations

    • NCCN BONE (p.77)